Individualized Treatment Effects with Censored Data via Fully
  Nonparametric Bayesian Accelerated Failure Time Models by Henderson, Nicholas C. et al.
ar
X
iv
:1
70
6.
06
61
1v
1 
 [s
tat
.M
E]
  2
0 J
un
 20
17
Individualized Treatment Effects with
Censored Data via Fully Nonparametric
Bayesian Accelerated Failure Time Models
Nicholas C. Henderson1, Thomas A. Louis2, Gary L. Rosner1,2, and Ravi
Varadhan1,2
1 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
2 Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University
Abstract
Individuals often respond differently to identical treatments, and characterizing
such variability in treatment response is an important aim in the practice of per-
sonalized medicine. In this article, we describe a non-parametric accelerated failure
time model that can be used to analyze heterogeneous treatment effects (HTE) when
patient outcomes are time-to-event. By utilizing Bayesian additive regression trees
and a mean-constrained Dirichlet process mixture model, our approach offers a flex-
ible model for the regression function while placing few restrictions on the baseline
hazard. Our non-parametric method leads to natural estimates of individual treat-
ment effect and has the flexibility to address many major goals of HTE assessment.
Moreover, our method requires little user input in terms of tuning parameter selection
or subgroup specification. We illustrate the merits of our proposed approach with a
detailed analysis of two large clinical trials for the prevention and treatment of con-
gestive heart failure using an angiotensin-converting enzyme inhibitor. The analysis
revealed considerable evidence for the presence of HTE in both trials as demonstrated
by substantial estimated variation in treatment effect and by high proportions of pa-
tients exhibiting strong evidence of having treatment effects which differ from the
overall treatment effect.
Keywords: Dirichlet Process Mixture; Ensemble Methods; Heterogeneity of Treatment
Effect; Interaction; Personalized Medicine; Subgroup Analysis.
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1 Introduction
While the main focus of clinical trials is on evaluating the average effect of a particular treat-
ment, assessing heterogeneity in treatment effect (HTE) across key patient sub-populations
remains an important task in evaluating the results of clinical studies. Accurate evalua-
tions of HTE that is attributable to variation in baseline patient characteristics offers many
potential benefits in terms of informing patient decision-making and in appropriately tar-
geting existing therapies. HTE assessment can encompass a wide range of goals: quantifi-
cation of overall heterogeneity in treatment response, identification of important patient
characteristics related to HTE, estimation of proportion who benefits from the treatment,
identification of patient sub-populations deriving most benefit from treatment, detection of
cross-over (qualitative) interactions, identifying the patients who are harmed by treatment,
estimation of individualized treatment effects, optimal treatment allocation for individuals,
and predicting treatment effect for a future patient.
Recently, there has been increasing methodology development in the arena of HTE
assessment. However, each developed method has been targeted to address one specific
goal of HTE analysis. For example, Xu et al. (2015), Foster et al. (2011) and Berger et al.
(2014) developed a method to identify patient subgroups whose response to treatment
differs substantially from the average treatment effect. Weisberg and Pontes (2015) and
Lamont et al. (2016) discuss estimation of individualized treatment effects. Zhao et al.
(2012) and Zhao et al. (2015) discuss construction of optimal individualized treatment rules
through minimization of a weighted classification error. Shen and Cai (2016) focus on
detection of biomarkers which are predictive of treatment effect heterogeneity. Thus, none
of the existing methods is sufficiently flexible to address multiple goals of HTE analysis.
Our aim in this paper is to construct a unified methodology for analyzing and explor-
ing HTE with a particular focus on cases where the responses are time-to-event. The
methodology is readily extended to continuous and binary response data. The motiva-
tion for investigating such a framework is the recognition that most, if not all, of the
above-stated goals of personalized medicine could be directly addressed if a sufficiently
rich approximation to the true data generating model for patient outcomes were available.
Bayesian nonparametric methods are well-suited to provide this more unified framework for
HTE analysis because they place few a priori restrictions on the form of the data-generating
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model and provide great adaptivity. Bayesian nonparametrics allow construction of flexible
models for patient outcomes coupled with probability modeling of all unknown quantities
which generates a full posterior distribution over the desired response surface. This allows
researchers to directly address a wide range of inferential targets without the need to fit a
series of separate models or to employ a series of different procedures. Our methodology
has the flexibility to address all of the HTE goals previously highlighted. For example,
the researchers could quantify overall HTE; identify most important patient characteristics
pertaining to HTE; estimate the proportion benefiting from, or harmed by, the treatment;
and predict treatment effect for a future patient.
Bayesian additive regression trees (BART) (Chipman et al. (2010)) provide a flexible
means of modeling patient outcomes without the need for making specific parametric as-
sumptions, specifying a functional form for a regression model, or for using pre-specified
patient subgroups. Because it relies on an ensemble of regression trees, BART has the
capability to automatically detect non-linearities and covariate interactions. As reported
by Hill (2011) in the context of using BART for causal inference, BART has the advantage
of exhibiting strong predictive performance in a variety of settings while requiring little
user input in terms of selecting tuning parameters. While tree-based methods have been
employed in the context of personalized medicine and subgroup identification by a variety
of investigators including, for example, Su et al. (2009), Loh et al. (2015), Chen and Chen
(2016), and Foster et al. (2011), BART offers several advantages for the analysis of HTE.
In contrast to many other tree-based procedures that use a more algorithmic approach,
BART is model-based and utilizes a full likelihood function and corresponding prior over
the tree-related parameters. Because of this, BART automatically generates measures of
posterior uncertainty; on the other hand, reporting uncertainty intervals is often quite
challenging for other frequentist tree-based procedures. In addition, because inference with
BART relies on posterior sampling, analysis of HTE on alternative treatment scales can be
done directly by simply transforming the desired parameters in posterior sampling. More-
over, any quantity of interest for individualized decisions or HTE evaluation can be readily
accommodated by the Bayesian framework. In this paper, we aim to utilize and incorporate
these advantages of BART into our approach for analyzing HTE with censored data.
Extensions of the original BART procedure to handle time-to-event outcomes have
been proposed and investigated by Bonato et al. (2011) and Sparapani et al. (2016). In
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Bonato et al. (2011), the authors introduce several sum-of-trees models and examine their
use in utilizing gene expression measurements for survival prediction. Among the survival
models proposed by Bonato et al. (2011) is an accelerated failure time (AFT) model with a
sum-of-trees regression function and a normally distributed residual term. Sparapani et al.
(2016) introduce a non-parametric approach that employs BART to directly model the
individual-specific probabilities of an event occurring at the observed event and censoring
times. In contrast to this approach, we propose a non-parametric version of the AFT model
which combines a sum-of-trees model with a Dirichlet process mixture model for the resid-
ual distribution. Such an approach has the advantage of providing great flexibility while
generating interpretable measures of covariate-specific treatment effects thus facilitating
the analysis of HTE.
Accelerated failure time (AFT) models (Louis (1981), Robins and Tsiatis (1992), or
Wei (1992)) represent an alternative to Cox-proportional hazards models in the analysis
of time-to-event data. AFT models have a number of features which make them appeal-
ing in the context of personalized medicine and investigating the comparative effective-
ness of different treatments. Because they involve a regression with log-failure times as
the response variable, AFT models provide a direct interpretation of the relationship be-
tween patient covariates and failure times. Moreover, treatment effects may be defined
directly in terms of the underlying failure times. Bayesian semi-parametric approaches
to the accelerated failure time model have been investigated by a number of authors
including Johnson and Christensen (1988), Kuo and Mallick (1997), Hanson and Johnson
(2002), and Hanson (2006). Kuo and Mallick (1997) assume a parametric model for the
regression function and suggest either modeling the distribution of the residual term or of
the exponential of the residual term via a Dirichlet process mixture model, while Hanson
(2006) proposed modeling the residual distribution with a Dirichlet process mixture of
Gamma densities. Our approach for modeling the residual distribution resembles that of
Kuo and Mallick (1997). Similar to these approaches, we model the residual distribution
as a location-mixture of Gaussian densities, and by utilizing constrained Dirichlet pro-
cesses, we constrain the mean of the residual distribution to be zero, thereby clarifying the
interpretation of the regression function.
This paper is organized as follows. In Section 2, we describe the general structure of
our nonparametric, tree-based accelerated failure time model, discuss its use in estimating
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individualized treatment effects, and describe our approach for posterior computation. Sec-
tion 3 examines several key inferential targets in the analysis of heterogeneous treatment
effects and how the nonparametric AFT model may be utilized to estimate these targets.
In Section 4, we detail the results of several simulation studies that evaluate our procedure
in terms of individualized treatment effect estimation, coverage, and optimal treatment
assignment. In Section 5, we examine a clinical trial involving the use of an ACE inhibitor,
and we demonstrate the use of our nonparametric AFT method to investigate heterogene-
ity of treatment effect in this study. We conclude in Section 6 with a few final remarks.
The methods described in this paper are implemented in the R package AFTrees, which
is available for download at http://www.hteguru.com/software.
2 The Model
2.1 Notation and Non-parametric AFT model
We assume that study participants have been randomized to one of two treatments which
we denote by either A = 0 or A = 1. We let x denote a p× 1 vector of baseline covariates
and let T denote the failure time. Given a censoring time C, we observe Y = min{T, C}
and a failure indicator δ = 1{T ≤ C}. The data consist of n independent measurements
{(Yi, δi, Ai,xi); i = 1, . . . , n}. Although we assume randomized treatment assignment here,
our approach may certainly be applied in observational settings. In such settings, however,
one should ensure that appropriate unconfoundedness assumptions (e.g., Hill (2011)) are
reasonable, so that the individualized treatment effects defined in (2) correspond to an
expected difference in potential outcomes under the two treatments.
The conventional accelerated failure time (AFT) model assumes that log-failure times
are linearly related to patient covariates. We consider here a non-parametric analogue of
the AFT model in which the failure time T is related to the covariates and treatment
assignment through
log T = m(A,x) +W, (1)
and where the distribution of the residual term W is assumed to satisfy E(W ) = 0. With
the mean-zero constraint on the residual distribution, the regression function m(A,x) has
a direct interpretation as the expected log-failure time given treatment assignment and
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baseline covariates.
The AFT model (1) leads to a natural, directly interpretable definition of the individ-
ualized treatment effect (ITE), namely, the difference in expected log-failure in treatment
A = 1 versus A = 0. Specifically, we define the ITE θ(x) for a patient with covariate vector
x as
θ(x) = E{log(T )|A = 1,x, m} −E{log(T )|A = 0,x, m}
= m(1,x)−m(0,x). (2)
The distribution of T in the accelerated failure time model (1) is characterized by both
the regression function m and the distribution FW of the residual term. In the following,
we outline a model for the regression function that utilizes additive regression trees, and
we describe a flexible nonparametric mixture model for the residual distribution FW .
2.2 Overview of BART
Bayesian Additive Regression Trees (BART) is an ensemble method in which the regression
function is represented as the sum of individual regression trees. The BART model for the
regression function relies on a collection of J binary trees {T1, . . . , TJ} and an associated set
of terminal node values Bj = {µj,1, . . . , µj,nj} for each binary tree Tj . Each tree Tj consists
of a sequence of decision rules through which any covariate vector can be assigned to one
terminal node of Tj by following the decision rules prescribed at each of the interior nodes.
In other words, each binary tree generates a partition of the predictor space in which each
element u = (A,x) of the predictor space belongs to exactly one of the nj terminal nodes
of Tj . The decision rules at the interior nodes of Tj are of the form {uk ≤ c} vs. {uk > c},
where uk denotes the k
th element of u. A covariate u that corresponds to the lth terminal
node of Tj is assigned the value µj,l and g(A,x; Tj, Bj) is used to denote the function that
returns µj,l ∈ Bj whenever (A,x) is assigned to the l
th terminal node of Tj .
The regression function m is represented in BART as a sum of the individual tree
contributions
m(A,x) =
J∑
j=1
g(A,x; Tj, Bj). (3)
Trees Tj and node values Bj can be thought of as model parameters with priors on these pa-
6
rameters inducing a prior on the regression function m via (3). To complete the description
of the prior on (T1, B1), . . . , (TJ , BJ), one needs to specify the following: (i) the distribution
on the choice of splitting variable at each internal node; (ii) the distribution of the splitting
value c used at each internal node; (iii) the probability that a node at a given node-depth d
splits, which is assumed to be equal to α(1+d)−β; and (iv) the distribution of the terminal
node values µj,l which is assumed to be µj,l ∼ Normal{0, (4k
2J)−1}. In order to ensure
that the prior variance for µj,l induces a prior on the regression function that assigns high
probability to the observed range of the data, Chipman et al. (2010) center and scale the
response so that the minimum and maximum values of the transformed response are −0.5
and 0.5 respectively. The distributions used for (i) and (ii) are discussed in Chipman et al.
(1998) and Chipman et al. (2010).
To denote the distribution on the regression functionm induced by the prior distribution
on Tj , Bj with parameter values (α, β, k) and J total trees, we use the notation
m ∼ BART(α, β, k, J).
2.3 Centered DP mixture prior
We model the density fW of W as a location-mixture of Gaussian densities with common
scale parameter σ. Letting G denote the distribution of the locations, we assume the
density of W (conditional on G and σ) can be expressed as
fW (w|G, σ) =
1
σ
∫
φ
(w − τ
σ
)
dG(τ), (4)
where φ(·) is the standard normal density function. The Dirichlet process (DP) is a widely
used choice for a nonparametric prior on an unknown probability distribution, and the
resulting DP mixture model for the distribution of W provides a flexible prior for the
residual density. Indeed, a DP mixture model similar to (4) was used by Kuo and Mallick
(1997) as a prior for a smooth residual distribution in a semi-parametric accelerated failure
time model.
Because of the zero-mean constraint on the residual distribution, the Dirichlet process
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is not an appropriate choice for a prior on G. A direct approach proposed by Yang et al.
(2010) addresses the problem of placing mean and variance constraints on an unknown
probability measure by utilizing a parameter-expanded version of the Dirichlet process
which the authors refer to as the centered Dirichlet process (CDP). As formulated by
Yang et al. (2010), the CDP with mass parameterM and base measure G0 has the following
stick-breaking representation
G =
∞∑
h=1
pihδτh
pih = Vh
∏
l<h
(1− Vl), h = 1, . . . ,∞
τh = τ
∗
h − µG∗ , h = 1, . . . ,∞
Vh ∼ Beta(1,M),
τ ∗h ∼ G0, h = 1, . . . ,∞, (5)
where µG∗ =
∑
∞
h=1 pihτ
∗
h and where δτ denotes a distribution that only consists of a point
mass at τ . We denote that a random measure G follows a centered Dirichlet process with
the notation G ∼ CDP(M,G0). From the above representation of the CDP, it is clear that
the mixture model (4) for W and the assumption that G ∼ CDP(M,G0) together imply
the mean-zero constraint, since the expectation of W can then be expressed as
E(W |G, σ) =
∞∑
h=1
τhpih =
∞∑
h=1
τ ∗hpih − µG∗
∞∑
h=1
pih,
which equals zero almost surely.
For the scale parameter of fW , we assume that σ
2 follows an inverse chi-square distribu-
tion, σ2 ∼ κν/χ2ν , with the default degrees of freedom ν set to ν = 3. Instead of specifying
a particular value for the mass parameter, we allow for learning about this parameter by
assuming M ∼ Gamma(ψ1, ψ2) where ψ1 and ψ2 refer to the shape and rate parameters of
Gamma distribution respectively.
Our non-parametric model that combines the BART model for the regression function
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and DP mixture model for the residual density can now be expressed hierarchically as
log Ti = m(Ai,xi) +Wi, Wi|τi, σ
2 ∼ N(τi, σ
2), for i = 1, . . . , n
m ∼ BART(α, β, k, J), τi|G ∼ G, G|M ∼ CDP(M,G0)
σ2 ∼ κν/χ2ν , M ∼ Gamma(ψ1, ψ2). (6)
In our implementation, the base measure G0 is assumed to be Gaussian with mean zero and
variance σ2τ . Choosing G0 to be conjugate to the Normal distribution simplifies posterior
computation considerably, but other choices of G0 could be considered. For example, a
t-distributed base measure could be implemented by introducing an additional latent scale
parameter.
2.4 Prior Specification
Prior for Trees and Terminal Node Parameters. For the hyperparameters of the trees
T1, . . . , TJ , we defer to the defaults suggested in Chipman et al. (2010); namely, α = 0.95,
β = 2, and J = 200. These default settings seem to work quite well in practice, and
in Section 5 we investigate the impact of varying J through cross-validation estimates of
prediction performance.
As discussed in Section 2.2, the original description of BART in Chipman et al. (2010)
employs a transformation of the response variable and sets the hyperparameter k to k = 2 so
that the regression function is assigned substantial prior probability to the observed range
of the response. Because our responses Yi are right-censored, we propose an alternative
approach to transforming the responses and to setting the prior variance of the terminal
node parameters. Our suggested approach is to first fit a parametric AFT model that
only has an intercept in the model and that assumes log-normal residuals. This produces
estimates of the intercept µˆAFT and the residual scale σˆAFT which allows us to define the
transformed “centered” responses as ytri = yi exp{−µˆAFT}. Turning to the prior variance
of the terminal node parameters µj,l, we assign the terminal node values µj,l the prior
distribution µj,l ∼ Normal{0, ζ
2/(4Jk2)}, where ζ = 4σˆAFT . This prior on µj,l induces a
Normal{0, 4σˆ2AFT/k
2} prior on the regression function m(A,x) and hence assigns approx-
imately 95% prior probability to the interval [−4k−1σˆAFT , 4k
−1σˆAFT ]. Thus, the default
setting of k = 2 assigns 95% prior probability to the interval [−2σˆAFT , 2σˆAFT ]. Note that
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assigning most of the prior probability to the interval [−2σˆAFT , 2σˆAFT ] is sensible because
this corresponds to the regression function for the “centered” responses ytri rather than the
original responses.
As described in Chipman et al. (1998) and Chipman et al. (2010), the prior on the split-
ting values c used at each internal node is uniform over the finite set of available splitting val-
ues for the chosen splitting variable. In implementations of BART, the number of possible
available splitting values is typically truncated so that it cannot exceed a pre-specified max-
imum value. The default setting used in the BayesTree package (Chipman and McCulloch
(2016)) has a maximum of 100 possible split points for each covariate, and the default is to
assign a uniform prior over potential split points that are equally spaced over the range of
the covariate. An alternative option offered in BayesTree is to, for each covariate, assign
a uniform prior over the observed quantiles of the covariate rather than the uniform prior
over the observed range of the covariate. Our default choice is to use the uniform prior
over covariate quantiles for the split point prior rather than the uniform prior over equally
spaced points. With this quantile-based prior, we found, in many simulations, improved
performance in terms of coverage.
Residual Distribution Prior. Under the assumed prior for the mass parameter, we have
E[M |ψ1, ψ2] = ψ1/ψ2 and Var(M |ψ1, ψ2) = ψ1/ψ
2
2 . We set ψ1 = 2 and ψ2 = 0.1 so that
the resulting prior on M is relatively diffuse with E[M |ψ1, ψ2] = 20, Var[M |ψ1, ψ2] = 200,
and a prior mode of 10.
When setting the defaults for the remaining hyperparameters κ and σ2τ , we adopt a
similar strategy to that used by Chipman et al. (2010) for BART when calibrating the
prior for the residual variance. There, they rely on a preliminary, rough overestimate σˆ2
of the residual variance parameter σ2 and define the prior for σ2 in such a way that there
is 1 − q prior probability that σ2 is greater than the rough estimate σˆ2. Here, q may be
regarded as an additional hyperparameter with the value of q determining how conservative
the prior of σ2 is relative to the initial estimate of the residual variance. Chipman et al.
(2010) suggest using q = 0.90 as the default whenever ν is set to ν = 3.
Similar to the approach described above, we begin with a rough over-estimate σˆ2W
of the variance of W to calibrate our choices of κ and σ2τ . A direct way of generating
the estimate σˆ2W is to fit a parametric AFT model with log-normal residuals and use the
resulting estimate of the residual variance, but other estimates could potentially be used.
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To connect the estimate σˆ2W with the hyperparameters κ and σ
2
τ described in (6), it is
helpful to first note that the conditional variance of the residual term can be expressed as
Var(W |G, σ) = σ2 + σ2τ
∞∑
h=1
pih
σ2τ
(τ ∗h − µG∗)
2. (7)
Our aim then is to select κ and σ2τ so that the induced prior on the variance of W as-
signs approximately 1 − q probability to the event
{
Var(W |G, σ) > σˆ2W
}
, where σˆ2W is
treated here as a fixed quantity. As an approximation to the distribution of (7), we use
the approximation that
∑
∞
h=1
πh
σ2τ
(τ ∗h − µG∗)
2 has a Normal{1, 2/(M + 1)} distribution (see
Yamato (1984) or Appendix A for further details about this approximation). Assuming
further that κ = σ2τ , we have that the variance of W is approximately distributed as
σ2τ [ν/χ
2
ν +N(1, {2(M + 1)}
−1)] where M ∼ Gamma(ψ1, ψ2), and with this approximation,
we can directly find a value of σ2τ = κ such that P
{
Var(W |G, σ) ≤ σˆ2W
}
= q. In contrast
to the q = 0.9 setting suggested in Chipman et al. (2010), we set the default to q = 0.5.
2.5 Posterior Computation
The original Gibbs sampler proposed in Chipman et al. (2010) works by sequentially up-
dating each tree while holding all other J − 1 trees fixed. As a result, each iteration of
the Gibbs sampler consists of 2J + 1 steps where the first 2J steps involve updating either
one of the trees Tj or terminal node parameters Mj and the last step involves updating the
residual variance parameter. The Metropolis-Hastings algorithm used to update the indi-
vidual trees is discussed in Chipman et al. (1998). Our strategy for posterior computation
is a direct extension of the original Gibbs sampler, viz., after updating trees and terminal
node parameters, we update the parameters related to the residual distribution. Censored
values are handled through a data augmentation approach where unobserved survival times
are imputed in each Gibbs iteration.
To sample from the posterior of the CDP, we adopt the blocked Gibbs sampling ap-
proach described in Ishwaran and James (2001). In this approach, the mixing distribution
G is truncated so that it only has a finite number of components H which is done by
assuming that, Vh ∼ Beta(1,M) for h = 1, . . . , H − 1 and VH = 1. This modification
of the stick-breaking weights ensures that
∑H
h=1 pih = 1. One advantage of using the
truncation approximation is that it makes posterior inferences regarding G straightfor-
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ward. Additionally, when truncating the stick-breaking distribution, using the CDP prior
as opposed to a DP prior does not present any additional challenges for posterior computa-
tion because the unconstrained parameters τ ∗h , µG∗ in (5) may be updated as described in
Ishwaran and James (2001) with the parameters of interest τh then being updated through
the simple transformation τh = τ
∗
h − µG∗ . The upper bound on the number of components
H should be chosen to be relatively large (as a default, we set H = 50), and in the Gibbs
sampler, the maximum index of the occupied clusters should be monitored. If a maximum
index equal to H occurs frequently in posterior sampling, H should be increased.
In the description of the Gibbs sampler, we use zi to denote a latent variable that
represents a transformed, imputed survival time, and we let yci denote the “complete-data”
survival times for the transformed survival times. That is, yc,tri = y
tr
i if δi = 1 and y
c,tr
i = zi
if δi = 0. For posterior computation related to the Dirichlet process mixture, we let Si
denote the cluster to which the ith observation has been assigned. An outline of the steps
involved in one iteration of our Gibbs sampler is provided below.
1. Update trees T1, . . . , TJ and node parameters B1, . . . , BJ using the Bayesian backfit-
ting approach of Chipman et al. (2010) with log yc,tri − τSi as the responses. Using
the updated T1, . . . , TJ and B1, . . . , BJ , update m(Ai,xi), i = 1, . . . , n.
2. Update cluster labels S1, . . . , Sn by sampling with probabilities
P (Si = h) ∝ pihφ
( log yc,tri −m(Ai,xi)− τh
σ
)
,
and tabulate cluster membership counts nh =
∑
i 1{Si = h}.
3. Sample stick-breaking weights Vh, h = 1, . . . , H − 1 as Vh ∼ Beta(αh, βh) where
αh = 1+nh and βh =M+
∑H
k=h+1 nk. Set VH = 1. The updated mixture proportions
are then determined by pih = Vh
∏
k<h(1− Vk), for h = 1, . . . , H .
4. Sample unconstrained cluster locations τ ∗h
τ ∗h ∼ Normal
( σ2τ
nhσ2τ + σ
2
n∑
i=1
{log yc,tri −m(Ai,xi)}1{Si = h},
σ2τσ
2
nhσ2τ + σ
2
)
,
and update constrained cluster locations τh = τ
∗
h − µG∗ , where µG∗ =
∑H
h=1 pihτ
∗
h .
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5. Update mass parameter M ∼ Gamma
(
ψ1+H−1, ψ2−
∑H−1
h=1 log(1−Vh)
)
and scale
parameter σ2 ∼ Inverse-Gamma
(
ν+n
2
, sˆ
2+κν
2
)
, where sˆ2 is given by
sˆ2 =
H∑
h=1
n∑
i=1
{log(yc,tri )−m(Ai,xi)− τh}
21{Si = h}.
6. For each i ∈ {k : δk = 0}, update zi by sampling
log zi ∼ Truncated-Normal(m(Ai,xi) + τSi , σ
2; log ytri ),
and set yc,tri = zi. Here, X ∼ Truncated-Normal(µ, σ
2; a) means that X is distributed
as Z|Z > a where Z ∼ Normal(µ, σ2).
Because we use the transformed responses log(ytri ) = log(yi)− µˆAFT in posterior computa-
tion, we add µˆAFT to the posterior draws of m(A,x) in the final output.
3 Posterior Inferences for the Analysis of Heteroge-
neous Treatment Effects
The nonparametric AFT model (6) generates a full posterior over the entire regression
function m(A,x) and the residual distribution. As such, this model has the flexibility to
address a variety of questions related to heterogeneity of treatment effect. In particular,
overall variation in response to treatment, proportion of patients likely to benefit from
treatment along with individual-specific treatment effects and survival curves may all be
defined in terms of parameters from the nonparametric AFT model.
3.1 Individualized Treatment Effects
As discussed in Section 2.1, a natural definition of the individual treatment effects in the
context of an AFT model is the difference in expected log-survival θ(x) = m(1,x)−m(0,x).
Draws from the posterior distribution of (m(A1,x1), . . . , m(An,xn)) allow one to compute
fully nonparametric estimates θˆ(xi) of the treatment effects along with corresponding 95%
credible intervals. As is natural with an AFT model, the treatment difference θ(x) in (2) is
examined on the scale of log-survival time, but other, more interpretable scales on which to
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report treatment effects could be easily computed. For example, ratios in expected survival
times ξ(x) defined by
ξ(x) = E
{
T |A = 1,x, m
}
/E
{
T |A = 0,x, m
}
= exp{θ(x)}
could be estimated via posterior output. Likewise, one could estimate differences in ex-
pected failure time by using both posterior draws of θ(x) and of the residual distribution.
Posterior information regarding treatment effects may be used to stratify patients into dif-
ferent groups based on anticipated treatment benefit. Stratification could be done using
the posterior mean, the posterior probability of treatment benefit, or some other relevant
measure.
3.2 Assessing Evidence Heterogeneity of Treatment Effect
As a way of detecting the presence of HTE, we examine the posterior probabilities of
differential treatment effect
Di = P
{
θ(xi) ≥ θ¯|y, δ
}
, (8)
along with closely related quantity
D∗i = max{1− 2Di, 2Di − 1}, (9)
where, in (8), θ¯ = n−1
∑n
i=1 θ(xi) is the conditional average treatment effect. Note that θ¯
is a model parameter that represents the average value of the individual θ(xi) and does not
represent a posterior mean. The posterior probability Di is a measure of the evidence that
the ITE θ(xi) is greater or equal to θ¯, and thus we should expect both high and low values
of Di in settings where substantial HTE is present. Note that D
∗
i approaches 1 as the value
of Di approaches either 0 or 1, and D
∗
i = 0 whenever Di = 1/2. For a given individual
i, we consider there to be strong evidence of a differential treatment effect if D∗i > 0.95
(equivalently, if Di ≤ 0.025 or Di ≥ 0.975), and we define an individual as having mild
evidence of a differential treatment effect provided that D∗i > 0.8 (equivalently, if Di < 0.1
or Di > 0.9). For cases with no HTE present, the proportion of patients exhibiting strong
evidence of differential treatment effect should, ideally, be zero or quite close to zero. For
this reason, the proportion of patients with D∗i > 0.95 can potentially be a useful summary
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measure for detecting the presence of HTE. In this paper, we do not explore explicit choices
of a threshold for this proportion, but we examine, through a simulation study in Section
4.2, the value of this proportion for scenarios for which no HTE is present and later compare
these simulation results with the observed proportion of patients in the SOLVD trials who
exhibit strong evidence of differential treatment effect. It is worth mentioning that the
quantity D∗i represents evidence that the treatment effect for patient i differs from the
overall treatment effect, and by itself, is not a robust indicator of HTE across patients in
the trial. Rather, the proportion of patients with high values of D∗i is what we use as a
means of assessing evidence for HTE.
It is worth noting that the presence or absence of HTE depends on the treatment effect
scale, and Di is designed for cases, such as the AFT model, where HTE is difference in
expected log-failure time. For example, it is possible to have heterogeneity on the log-
hazard ratio scale while having zero differences in the ITEs θ(xi) across patients.
3.3 Characterizing Heterogeneity of Treatment Effect
Variability in treatment effect across patients in the study is a prime target of interest when
evaluating the extent of heterogeneous treatment effects from the results of a clinical trial.
Assessments of HTE can be used to evaluate consistency of response to treatment across
patient sub-populations or to assess whether or not there are patient subgroups that appear
to respond especially strongly to treatment. In more conventional subgroup analyses (e.g.,
Jones et al. (2011)), heterogeneity in treatment effect is frequently reported in terms of
the posterior variation in treatment effect across patient subgroups. While the variance
of treatment effect is a useful measure, especially in the context of subgroup analysis,
we can provide a more detailed view of HTE by examining the full distribution of the
individualized treatment effects defined by (2) where the distribution may be captured by
the latent empirical distribution function Hn(t) =
1
n
∑n
i=1 1{θ(xi) ≤ t}. Such an approach
to examining the “distribution” of a large collection of parameters has been explored in
Shen and Louis (1998) and Louis and Shen (1999). The distribution function Hn(t) may
be regarded as a model parameter that can directly estimated by
Hˆn(t) =
1
n
n∑
i=1
P{θ(xi) ≤ t|y, δ}, (10)
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and credible bands for Hn(t) may be obtained from posterior samples. For improved
visualization of the spread of treatment effects, it is often better to display a density
function hˆn(t) associated with (10) which could be obtained through direct differentiation
of (10). Alternatively, a smooth estimate can be found by computing the posterior mean
of a kernel function Kλ with bandwidth λ
hˆn(t) =
1
n
n∑
i=1
E
{
Kλ
(
t− θ(xi)
)∣∣∣y, δ
}
. (11)
The posterior of Hn(t) provides a direct assessment of the variation in the underlying
treatment effects, and as such, serves as a useful overall evaluation of HTE.
3.4 Proportion Who Benefits
Another quantity of interest related to HTE is the proportion of patients who benefit from
treatment. Such a measure has a direct interpretation and is also a useful quantity for as-
sessing the presence of cross-over or qualitative interactions, namely, cases where the effect
of treatment has the opposite sign as the overall average treatment effect. That is, for situ-
ations where an overall treatment benefit has been determined, a low estimated proportion
of patients benefiting may be an indication of the existence of cross-over interactions.
Using the treatment differences θ(x), the proportion who benefit may be defined as
Q =
1
n
n∑
i=1
1{θ(xi) > 0}. (12)
Alternatively, one could define the proportion benefiting relative to a clinically relevant
threshold ε > 0, i.e., Qǫ = n
−1
∑n
i=1 1{θ(xi) > ε}. The posterior mean of Q is an average
over patients of the posterior probabilities of treatment benefit pˆi = P{θ(xi) > 0|y, δ}.
Posterior probabilities of treatment benefit can be used for treatment assignment (pˆi > 1/2
vs. pˆi ≤ 1/2), or as an additional summary measure of HTE where one, for example, could
tabulate the proportion very likely to benefit from treatment pˆi > 0.99 or the proportion
likely to benefit from treatment pˆi > 0.90.
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3.5 Treatment Allocation
Individualized treatment recommendations may be directly obtained by combining a fit of
the non-parametric AFT model with a procedure minimizing the posterior risk associated
with a chosen loss function. For instance, when trying to minimize the proportion of treat-
ment misclassifications, one would assign treatment based on whether or not the posterior
probability of the event {θ(x) > 0} was greater than 0.5. Alternatively, one could optimize
a weighted mis-classification loss where mis-classifications are weighted by the correspond-
ing magnitude |θ(x)| of the treatment effect, in which case the optimal treatment decision
would depend on the posterior mean of 1{θ(x) > 0}×|θ(x)|. Though we do not explore the
issue in this paper, such approaches to inividualized treatment allocation could potentially
be used, for example, in the development of adaptive randomization strategies for clinical
trials.
3.6 Individual-level Survival Functions
In terms of the quantities of the non-parametric AFT model (6), individual-specific survival
curves are defined by
P{T > t|A,x, m,G, σ} = 1−
∫
Φ
( log t−m(A,x)− τ
σ
)
dG(τ).
Using the truncated distribution GH as an approximation in posterior computation, the
survival curves are given by
P{T > t|A,x, m,GH , σ} = 1−
H∑
h=1
Φ
( log t−m(A,x)− τh
σ
)
pih, (13)
which may be directly estimated using posterior draws of the regression function and τh, pih.
3.7 Partial Dependence and Variable Importance
Partial dependence plots are a useful tool for visually assessing the dependence of an
estimated function on a particular covariate or set of covariates. As described in Friedman
(2001), such plots demonstrate the way an estimated function changes as a particular
covariate varies while averaging over the remaining covariates.
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For the purposes of examining the impact of a covariate on the treatment effects, we
define the partial dependence function for the lth covariate as
ρl(z) =
1
n
n∑
i=1
θ(z,xi,−l),
where (z,xi,−l) denotes a vector where the l
th component of xi has been removed and
replaced with the value z. Estimated partial dependence functions ρˆl(z) with associated
credible bands may be obtained directly from MCMC output.
4 Simulations
To evaluate the performance of the non-parametric, tree-based AFT method, we performed
three simulation studies. For performance related to quantifying HTE, we recorded the fol-
lowing measures: root mean-squared error of the estimated individualized treatment effects,
the proportion of patients allocated to the wrong treatment, and the average coverage of the
confidence/credible intervals. For each simulation, the root mean-squared error (RMSE)
is measured as
√
n−1
∑n
i=1{θˆ(xi)− θ(xi)}
2, where θ(xi) is as defined in Section 2.1, and
θˆ(xi) is an estimate of the ITE. For treatment classification indicators R1, . . . , Rn (i.e.,
Ri = 1 if patient i is classified as benefiting from treatment A = 1 rather than A = 0), the
proportion mis-classified (MCprop) is calculated within each simulation replication as
MCprop = n−1
n∑
i=1
1{θ(xi) ≤ 0}Ri + n
−1
n∑
i=1
1{θ(xi) > 0}(1− Ri).
Coverage proportions are measured as the average coverage over individuals, namely,
n−1
∑n
i=1 1{θˆ
L(xi) ≤ θ(xi) ≤ θˆ
U (xi)}, for interval estimates [θˆ
L(xi), θˆ
U(xi)].
For the performance measures of RMSE and coverage proportions, we compared our
tree-based non-parametric AFT model (NP-AFTree) with the semi-parametric AFT model
(SP-AFTree) where the BART model is used for the regression function and the residual
distribution is assumed to be Gaussian. In addition, we compared the NP-AFTree proce-
dure with a parametric AFT model (Param-AFT) which assumes a linear regression with
treatment-covariate interactions and log-normal residuals.
For both the NP-AFTree and SP-AFTree methods, 7, 000 MCMC iterations were used
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with the first 2, 000 treated as burn-in steps. For both of these, the default parameters
(i.e., q = 0.5, k = 2, J = 200) were used for each simulation scenario.
4.1 AFT simulations based on the SOLVD trials
In our first set of simulations, we use data from the SOLVD trials (The SOLVD Investigators
(1991)) to guide the structure of the simulated data. Further details regarding the SOLVD
trials are discussed in Section 5. To generate our simulated data, we first took two ran-
dom subsets of sizes n = 200 and n = 1, 000 from the SOLVD data. For each subset, we
computed estimates m˜200(A,x) and m˜1000(A,x) respectively of the regression function for
A ∈ {0, 1} using the non-parametric AFT Tree model. Simulated responses yk were then
generated as
log yk = Ak(n)m˜
n(0,xk(n)) + (1− Ak(n))m˜
n(1,xk(n))− 0.4 +Wk, k = 1, . . . , n, (14)
where the regression function was fixed across simulation replications and (Ak(n),xk(n))
corresponds to the kth patient’s treatment assignment and covariate vector in the random
subset with n patients. The constant −0.4 in (14) was added so that there was a substantial
fraction of simulated patients would have an underlying ITE θ(x) = m˜(1,x)−m˜(0,x)−0.4
less than zero. In particular, 44.1% of patients in the n = 1, 000 simulations had an
underlying value of θ(x) greater than zero while 88.5% had positive values of θ(x). For
the distribution of Wk, we considered four different choices: a Gaussian distribution, a
Gumbel distribution with mean zero, a “standardized” Gamma distribution with mean
zero, and a mixture of three t-distributions with 3 degrees of freedom for each mixture
component. The parameters of each of the four distributions were chosen so that the
variances were approximately equal. The levels of censoring was varied across three levels:
none, light censoring (approximately 15% of cases censored), and heavy censoring (45% of
cases censored).
Mean-squared error, classificiation (MCprop), and coverage results are shown in Figure
1. More detailed results from this simulation study are displayed in the supplementary
material. As may be inferred from Figure 1, the NP-AFTree method consistently performs
better in terms of root mean-squared error and misclassification proportion than the SP-
AFTree procedure. Moreover, while not apparent from the figure, the NP-AFTree approach
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Figure 1: Simulations based on the SOLVD trial data. Results are based on 50 simulation replications.
Root mean-squared error, Misclassification proportion, and empirical coverage are shown for each method.
Performance measures are shown for the non-parametric tree-based AFT (NP-AFTree) method, the semi-
parametric tree-based AFT (SP-AFTree), and the parametric, linear regression - based AFT (Param-AFT)
approach. Four different choices of the residual distribution were chosen: a Gaussian distribution, a Gumbel
distribution with mean zero, a “standardized” Gamma distribution with mean zero, and a mixture of three
t-distributions with 3 degrees of freedom for each mixture component.
performs just as well as SP-AFTree, even when the true residual distribution is Gaussian
(see the supplementary material). For each residual distribution, the advantage of NP-
AFTree over SP-AFTree is more pronounced for the smaller sample sizes settings n =
200, with closer performance for the n = 1, 000 cases. While root mean-squared error
and misclassification seem to be comparable between NP-AFTree and SP-AFTree for the
n = 1, 000 settings, the coverage for NP-AFTree is consistently closer to the desired 95%
level and is greater than 95% for nearly all settings. When n = 200, coverage often differs
substantially from 95%, but in these cases, BART is quite conservative in the sense that
coverage is typically much greater than 95%.
4.2 Several “Null” Simulations
We considered data generated from several “null” cases where the simulation scenarios were
designed so that no HTE was present. For these simulations, we consider data generated
20
from four AFT models and data generated from a Cox proportional hazards model. In
these “null” simulations, we are primarily interested in the degree to which the NP-AFTree
procedure “detects” spurious HTE in situations where no HTE is present in the underly-
ing data generating model. The AFT models used for the simulations assumed a linear
regression function with no treatment-covariate interactions
log yk = β0 + β1Ai +
∑
k
βkxik +Wi, (15)
and the hazard functions for the Cox model simulations similarly took the form
h(t|x) = h0(t) exp
(
β0 + β1Ai +
∑
k
βkxik
)
. (16)
Although there may be a degree of heterogeneity in θ(x) for the Cox proportional hazards
model (16), it is still worthwhile to investigate the behavior of Di when there is no HTE
when treatment effects are defined in terms of hazard ratios.
The parameters in (15) were first estimated from the SOLVD data using a parametric
AFT model with log-normal residuals. Here, we estimated the parameters in (15) separately
using the same fixed subsets of size n = 1, 000 and n = 200 used in Section 4.1. The
parameters were fixed across simulation replications. For the AFT models, we considered
the same four choices of the residual term distribution as in Section 4.1. The parameters
for the hazard functions in (16) were found by fitting a Cox proportional hazards model
to the same two subsets of size n = 200 and n = 1, 000 from the SOVLD trials data,
and these parameters were fixed across simulation replications. The cumulative baseline
hazard function used to generate the Cox proportional hazards simulations was found by
using Breslow’s estimator. In these simulations, we ran the NP-AFTree procedure with
2, 000 MCMC iterations with the first 1, 000 treated as burn-in steps.
For each null simulation scenario, we computed the posterior probabilities of differential
treatment effect Di (see equations (8) and 9) and tabulated the percentage of patients with
either strong evidence of differential treatment effect (i.e., D∗i > 0.95) or mild evidence
(i.e., D∗i > 0.8). Table 1 shows, for each null simulation scenario, the average proportion
of individuals exhibiting strong evidence of a differential treatment effect and the average
proportion of individuals exhibiting mild evidence of a differential treatment effect. As
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displayed in Table 1, the average percentage of individuals showing strong evidence of
differential treatment effect is less than 0.22% for all simulation settings. Moreover, the
percentages of cases with mild evidence of differential treatment effect was fairly modest.
The average percentage of patients with mild evidence was less than 3.9% for all except
one simulation scenario, and most of the simulation scenarios had, on average, less than 3%
of patients exhibiting mild evidence of differential treatment effect. Null simulations with
n = 200 tended to have much fewer cases of strong or mild evidence than those simulations
with n = 1, 000. The results presented in Table 1 suggest that the NP-AFTree procedure
rarely reports any patients as having strong evidence of differential treatment effects for
situations where HTE is absent.
Table 1: Simulation for settings without any HTE present. Results are based on 100 simulation replica-
tions. Average percentage of patients exhibiting strong evidence (SE) of differential treatment effect (i.e.
Di ≥ 0.95 or Di ≤ 0.05) and average percentage of patients exhibiting mild evidence (ME) of differential
treatment effect (i.e., Di ≥ 0.8 or Di ≤ 0.2). Results are shown for AFT models with the same four
residual distributions used in the simulations from Section 4.1 and for a Cox-proportional hazards model
with no treatment-covariate interactions. Censoring levels were varied according to: none, light censoring
(approximately 25% of cases censored), and heavy censoring (approximately 45% of cases censored).
Normal Gumbel Std-Gamma T-mixture Cox-PH
n Censoring SE ME SE ME SE ME SE ME SE ME
200 none 0.000 0.095 0.000 0.040 0.000 0.070 0.000 0.060 0.000 0.140
200 light 0.000 0.095 0.000 0.000 0.075 0.350 0.000 0.380 0.000 0.015
200 heavy 0.000 0.020 0.000 0.000 0.000 0.000 0.000 0.055 0.000 0.290
1000 none 0.000 0.803 0.073 2.066 0.092 1.483 0.161 3.087 0.176 3.824
1000 light 0.061 1.989 0.015 0.967 0.213 2.674 0.066 3.176 0.111 3.405
1000 heavy 0.002 1.253 0.000 0.484 0.030 1.176 0.123 2.953 0.135 2.688
4.3 Friedman’s Randomly Generated Functions
In these simulations, we further evaluate the performance of the NP-AFTree using randomly
generated nonlinear regression functions. To generate these random functions, we use a
similar approach to that used in Friedman (2001) to assess the performance of gradient
boosted regression trees. This approach allows us to test our approach on a wide range
of difficult nonlinear regression functions that have higher-order interactions. For these
simulations, we generated random regression functions m(A,x) via
m(A,xi) = F0(xi) + Aiθ(xi),
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where the functions F0(x) and θ(x) are defined as
F0(xi) =
10∑
l=1
a1lg1l(z1l) and θ(xi) =
5∑
l=1
a2lg2l(z2l). (17)
The coefficients in (17) are generated as a1l ∼ Uniform(−1, 1) and a2l ∼ Uniform(−0.2, 0.3).
The vector zijl is a subset of xi of length njl where the randomly selected indices used to
construct the subset of xi are the same for each i. The subset sizes are generated as
njl = min(⌊rl + 1.5⌋, 10) where rjl ∼ Exponential(1/2).
gjl(zjl) = exp
{
−
1
2
(zjl − µjl)
TVjl(zjl − µjl)
}
.
The elements µjlk of the vector µjl are generated as µjlk ∼ Normal(0, 1), and the ran-
dom matrix Vjl is generated as Vjl = UjlDjlU
T
jl, where Djl = diag{djl,1, . . . , djl,njl} with√
djl,k ∼ Uniform(0.1, 2) and where Ujl is a random orthogonal matrix. We generated the
covariate vectors xi = (xi,1, . . . , xi,20)
T of length 20 independently with xi,k ∼ Normal(0, 1).
Treatment assignments Ai were generated randomly with P (Ai = 1) = 1/2. These simu-
lation settings imply that θ(x) is positive for roughly 87% of individuals. The parameters
of the residual distributions were chosen so that the variances of each distribution were
approximately equal.
Figure 2 shows simulation results for NP-AFTree, SP-AFTree, and the parametric AFT
model. In this figure, we observe that root-mean squared error is broadly the same for the
NP-AFTree and SP-AFTree methods with each of the tree methods exhibiting much better
performance than Param-AFT. This similarity in RMSE of SP-AFTree and NP-AFTree
seems attributable to the difficulty of estimating these regression functions which seems to
overwhelm most of the advantages of more flexible modeling of the residual distribution.
Compared to SP-AFTree, NP-AFTree shows modestly better classification performance,
particularly for settings that have non-Gaussian residual distributions and for settings
with the larger (n = 1, 000) sample size. However, as in the simulations of Section 4.1,
there seems to be no advantage here of either NP-AFTree, SP-AFTree, or Param-AFT over
the naive treatment allocation approach when the sample size is n = 200. These results
suggest that fairly large sample sizes may be needed for there to be any advantage over
the naive approach which simply allocates individuals to the treatment having the more
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Figure 2: Simulations for AFT models with randomly generated regression functions. Results are based on
50 simulation replications. Root mean-squared error, misclassification proportion, and empirical coverage
are shown for each method. Performance measures are shown for the non-parametric tree-based AFT (NP-
AFTree) method, the semi-parametric tree-based AFT (SP-AFTree), and the parametric, linear regression
- based AFT (Param-AFT) approach. Four different choices of the residual distribution were chosen: a
Gaussian distribution, a Gumbel distribution with mean zero, a “standardized” Gamma distribution with
mean zero, and a mixture of three t-distributions with 3 degrees of freedom for each mixture component.
beneficial overall treatment effect. For NP-AFTree the average coverage is consistently a
few percentage points below the desired 95% level suggesting that modest under-coverage
can occur in certain settings.
5 HTE in the SOLVD Trials
The Studies of Left Ventricular Dysfunction (SOLVD) were devised to investigate the effi-
cacy of the angiotensin-converting enzyme (ACE) inhibitor enalapril in a target population
with low left-ventricular ejection fractions. The SOLVD treatment trial (SOLVD-T) en-
rolled patients determined to have a history of overt congestive heart failure, and the
SOLVD prevention trial (SOLVD-P) enrolled patients without overt congestive heart fail-
ure. In total, 2, 569 patients were enrolled in the treatment trial while 4, 228 patients were
enrolled in the prevention trial. The survival endpoint that we examine in our analysis is
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time until death or hospitalization where time is reported in days from enrollment.
In our analysis of the SOLVD-T and SOLVD-P trials, we included 18 patient covariates
common to both trials, in addition to using treatment and study indicators as covariates.
Of these 18 covariates, 8 were continuous covariates, 8 were binary covariates, one covariate
was categorical with three levels, and one was categorical with four levels. In our analysis,
we dropped those patients who had one or more missing covariate values, which resulted
in 548 patients being dropped from the total of 6, 797 enrolled in either trial.
5.1 Cross-Validation across Hyperparameter Settings
When fitting the NP-AFT model with the SOLVD data, we considered several settings
for the hyperparameters, and for each setting of the hyperparameters, we computed cross-
validation scores to evaluate performance in terms of predicting patient outcomes and in
terms of characterizing HTE. For evaluating predictions of patient outcomes, we utilize, as
in Tian et al. (2014) and Tian et al. (2007), a direct measure of absolute prediction error.
In particular, for the kth test set Dk, we compute the following cross-validation score
CV absk =
1
nk
∑
i∈Dk
δi
Vˆ (Yi|Ai,xi)
∣∣∣ log Yi − mˆ−Dk(Ai,xi)
∣∣∣, (18)
where nk is the number of patients in Dk and mˆ−Dk(A,x) is the regression function esti-
mated from the kth training set. The weights used in (18) Vˆ (Yi|Ai,xi) are estimates of the
censoring probability V (t|A,x) = P (C > t|A,x). The total K-fold cross-validation error is
computed as K−1
∑K
k=1CV
abs
k .
Figure 3 shows results from applying cross-validation to the SOLVD trials with 36
different settings of the hyperparameters. The censoring probabilities Vˆ (Yi|A,xi) used as
weights in (18) were estimated using a Cox model. The 36 hyperparameter settings were
generated by varying the hyperparameter q which determines the parameters of the base
distribution G0, the hyperparameter k that determines the prior variance of the node values,
and the number of trees J . We varied q across the four levels, q = 0.25, 0.5, 0.90, 0.99; k
across the three levels, k = 1, 2, 3; and the number of trees J across the three levels,
J = 50, 200, 400. Ten-fold cross-validation was used for each setting of the hyperparameters.
As shown in Figure 3, the hyperparameter q appears to play the most important role in
driving the differences in cross-validation performance while larger values of the shrinkage
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Figure 3: Ten-fold cross-validation for the SOLVD-T and SOLVD-P trials using the mean absolute
deviation estimate defined in (18). Twenty seven settings of the hyperparameters are considered. The
cross-validation score for the default setting of the hyperparameters is marked with an ×. The horizontal
red line denotes the ten-fold cross-validation score of a parametric AFT model with log-normal errors where
a linear regression model with treatment-covariate interactions was assumed.
parameter k seem to have a modest beneficial effect in the q = 0.25 and q = 0.5 settings.
The settings with the very conservative choice of q = 0.99 exhibit poor performance giving
similar cross-validation scores as a parametric AFT model with an assumed linear model for
the regression function. The setting with the best cross-validation score was q = 0.5, k =
3, J = 400. This cross-validation score, however, was not notably different than many of
the settings with either q = 0.25 and q = 0.5. For this reason, we continued to use the
default setting of q = 0.5, k = 2, and J = 200 in our analysis of the SOLVD trials.
5.2 Individualized Treatment Effect Estimates and Evidence for
HTE
Figure 4 shows point estimates of the ITEs θ(x) for patients in both the SOLVD-T and
SOLVD-P trials. While the plot in Figure 4 indicates a clear, overall benefit from the
treatment, the variation in the ITEs suggests substantial heterogeneity in response to
treatment.
Examining the posterior probabilities of differential treatment effect offers further ev-
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Figure 4: Posterior means of θ(x) (red points) with corresponding 95% credible intervals for patients in
the SOLVD-T and SOLVD-P trials.
idence for the presence of meaningful HTE in the SOLVD trials. Table 2 shows that, in
the SOLVD-T trial, approximately 19% of patients had strong evidence of a differential
treatment effect (i.e. D∗i > 0.95), and approximately 42% of patients had mild evidence of
a differential treatment effect (i.e., D∗i > 0.80). In the SOLVD-P trial approximately 7%
of patients had strong evidence of a differential treatment effect while approximately 32%
had mild evidence. Comparison of these percentages with the results from the simulations
of Section 4.2 suggests the presence of HTE. In the null simulation scenarios of Section
4.2, the proportion of cases with strong evidence of differential treatment was very close to
zero. Thus, the large proportion of patients with strong evidence for differential treatment
effect is an indication of the presence of HTE in the SOLVD trials that deserves further
exploration.
5.3 Characterizing Variation in Treatment Effect
Figure 5 displays a histogram of the posterior means of the treatment ratios ξ(x) =
E(T |A = 1,x, m)/E(T |A = 0,x, m), for each patient in the SOLVD-T and SOLVD-P
trials. In contrast to the ITE scale used in Figure 4, defining the ITEs in terms of the
ratios of expected failure times may provide a more interpretable scale by which to de-
scribe HTE. As may be inferred from the histogram in Figure 5, nearly all patients have a
27
positive estimated treatment effect with 98.9% having an estimated value of ξ(xi) greater
than one. Of those in the SOLVD-T trial, all the patients had E{ξ(xi)|y, δ} > 1, and
98.2% of patients in the SOLVD-P trial had E{ξ(xi)|y, δ} > 1.
Figure 5 also reports the smoothed estimate hˆn(t) of the distribution of the treatment
effects separately for the two trials. These smoothed posterior estimates of the treatment
effect distribution were computed as described in equation (11) where posterior samples
of ξ(xi) were used in place of θ(xi). Note that the hˆn(t) shown in Figure 5 are estimates
of the distribution of the underlying treatment effects and do not represent the posterior
distribution of the overall treatment effects within each trial. As expected, the variation
in treatment effect suggested by the plots of hˆn(t) in Figure 5 is greater than the variation
exhibited by the posterior means of ξ(xi). The estimates hˆn(t) provide informative char-
acterizations of the distribution of treatment effects in each trial especially for visualizing
the variability in treatment effects in each trial. The posterior median of the standard
deviation of treatment effect
√∑
i{ξ(xi)− ξ¯}
2 was 0.45 for the SOLVD-T and 0.34 for the
SOLVD-P trial.
5.4 Proportion Benefiting
We can use (12) to estimate the proportion of patients benefiting in each trial. The es-
timated proportions of patients (i.e., the posterior mean of Q in (12)) benefiting were
95.6% and 89.1% in the SOLVD-T and SOLVD-P trials respectively. These proportions
are approximately equal to the area under the curve of hˆn(t) for t ≥ 1 in Figure 5.
Table 2 shows a tabulation of patients according to evidence of treatment benefit. In
both trials, all patients have at least a 0.25 posterior probability of treatment benefit (i.e.
P{ξ(xi) > 1|y, δ} > 0.25). In the treatment trial, 76% percent of patients exhibit a
posterior probability of benefit greater than 0.95, and the percentage for the prevention
trial is 44%.
5.5 Individual-level Survival Functions
Figure 6 shows estimated survival curves for randomly selected patients from the SOLVD
treatment trial. Averages of these individual-level survival curves are computed for each
treatment arm and compared with the corresponding Kaplan-Meier estimates of survival.
It is apparent from Figure 6 that considerable heterogeneity in patient risk is present.
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Figure 5: Histogram of point estimates (i.e., posterior means) of the treatment effects ξ(x) = eθ(x) and
smooth posterior estimates hˆn(t) of the treatment effect distribution. The histogram is constructed using
all point estimates from both the SOLVD treatment and prevention trials. Smooth estimates, hˆn(t) , of the
distribution of treatment effects were computed as described in equation for the two trials separately. The
kernel bandwidth λ for each trial was chosen using the rule λ = [0.9×min(σˆξ, ˆIQRξ)]/[1.34×n
1/5
t ], where
σˆξ and ˆIQRξ are posterior means of the standard deviation and inter-quartile range of ξ(xi) respectively
and where nt is the trial-specific sample size.
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SOLVD Treatment Trial SOLVD Prevention Trial
P{ξ(xi) > 1|y, δ} ∈ (0.99, 1] 51.38 20.47
P{ξ(xi) > 1|y, δ} ∈ (0.95, 0.99] 24.69 23.71
P{ξ(xi) > 1|y, δ} ∈ (0.75, 0.95] 20.08 41.98
P{ξ(xi) > 1|y, δ} ∈ (0.25, 0.75] 3.85 13.84
P{ξ(xi) > 1|y, δ} ∈ [0, 0.25] 0.00 0.00
D∗i > 0.95 19.36 7.30
D∗i > 0.80 41.93 31.58
Table 2: Tabulation of posterior probabilities of treatment benefit and posterior probablities of dif-
ferential treatment effect Di = P{ξ(xi) ≥ ξ¯|y, δ}. For each trial, the empirical percentage of pa-
tients whose estimated posterior probability of treatment benefit lies within each of the intervals
(0.99, 1], (0.95, 0.99], (0.75, 0.95], (0.25, 0.75], and [0, 0.25] is reported. In addition, the percentages of pa-
tients in each trial that exhibit “strong” (i.e., D∗i > .95) and “mild” (i.e., Di > 0.80) evidence of differential
treatment effect are shown.
Indeed, in the control arm, 20% percent of patients had an estimated median survival time
less than 500 days, 54% had between 500 and 1500 days, and 26% had an estimated median
survival time of more than 1500 days.
5.6 Exploring Important Variables for HTE
To explore the patient attributes important in driving differences in treatment effect, we use
a direct approach similar to the “Virtual Twins” method used by Foster et al. (2011) in the
context of subgroup identification. In Foster et al. (2011), the authors suggest a two-stage
procedure where one first estimates treatment difference for each individual and then,
using these estimated differences as a new response variable, one estimates a regression
model in order to identify a region of the covariate space where there is an enhanced
treatment effect. Similarly, to examine important HTE variables, we first fit the full non-
parametric AFT model to generate posterior means θˆ(xi) of the individualized treatment
effect for each patient. Then, we estimate a regression using the previously estimated θˆ(x)
as the response variable and the patient covariates (except for treatment assignment) as the
predictors. Because the treatment difference θ(x) should only depend on covariates that
are predictive of HTE, using the unobserved θ(xi) as the responses in a regression with
the patient covariates as predictors represents a direct and efficient approach to exploring
variables involved in driving treatment effect heterogeneity.
To investigate the important HTE variables in the SOLVD trials using the virtual twins
approach, we fit a linear regression using weighted least squares with θˆ(xi) as the responses
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Figure 6: Estimates of individual-specific survival curves for selected patients from the SOLVD treatment
trial. For each patient, the posterior mean of the survival functions P{T > t|A,x,m,GH , σ} as defined
in (13) are plotted. The solid black and red survival curves are the average by treatment group of these
estimated individual-specific surves. The dashed survival curves are the Kaplan-Meier estimates for each
treatment group.
and where the residual variances were assumed proportional to the posterior variances of
θ(xi). In this weighted regression, all covariates were normalized to have zero mean and
unit variance. The patient covariates with the five largest estimated coefficients in absolute
value were as follows: baseline ejection fraction, history of myocardial infarction, baseline
creatinine levels, gender, and diabetic status. Figure 7 displays partial dependence plots for
ejection fraction and creatinine along with the posterior distribution of the average treat-
ment effect in the male/female groups and the subgroups defined by history of myocardial
infarction. The partial dependence plots clearly demonstrate an enhanced treatment effect
for those patients with lower baseline ejection fraction. The strongest change in treatment
effect occurs in the ranges 0.20 − 0.30. The comparisons according to gender shown in
Figure 7 show greater treatment benefit in men vs. women for both SOLVD trials.
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Figure 7: Smoothed partial dependence plots for ejection fraction and creatinine levels, and posterior
distributions of treatment effect for men vs. women and for those with a history of myorcardial infarction
vs. those with no history of myocardial infarction (HIMI vs. No HIMI).
6 Discussion
In this paper, we have described a flexible, tree-based approach to examining heterogeneity
of treatment effect with survival endpoints. This method produces estimates of individual-
ized treatment effects with corresponding credible intervals for AFT models with an arbi-
trary regression function and residual distribution. Moreover, we have demonstrated how
this framework provides a useful framework for addressing a variety of other HTE-related
questions. When using the default hyperparameter settings, the method only requires
the user to input the survival outcomes, treatment assignments, and patient covariates.
As shown in several simulation studies, the default settings exhibit strong predictive per-
formance and good coverage properties. Though quite flexible, our non-parametric AFT
model does entail some assumptions regarding the manner in which the patient covariates
modify the baseline hazard. Hence, it would be worth further investigating the robustness
of the nonparametric AFT method to other forms of model misspecification such as cases
where neither an AFT or a Cox proportional hazards assumption holds or cases where the
residual distribution depends on the patient covariates.
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In addition to describing a novel non-parametric AFT model, we examined a num-
ber of measures for reporting HTE including the distribution of individualized treatment
effects, the proportion of patients benefiting from treatment, and the posterior probabil-
ities of differential treatment effect. Each have potential uses in allowing for more re-
fined interpretations of clinical trial results. The argument has been made by some (e.g.,
Kent and Hayward (2007)) that the positive results of some clinical trials are driven sub-
stantially by the outcomes of high-risk patients. In such cases, the posterior distribution of
the ITEs along with the estimated proportion benefiting may help in clarifying the degree
to which lower risk patients are expected to benefit from the proposed treatment. In Sec-
tion 4.2, we explored the use of posterior probabilities of differential treatment effect as a
means of detecting the presence of HTE. Such measures show potential for evaluating the
consistency of treatment and for assessing whether or not further investigations into HTE
are warranted.
As described in this paper, the BART-based nonparametric AFT model only works
when no missing values of the patient covariates occur. Though not explored in this pa-
per, tree-based methods have the potential to provide intuitive, automatic approaches for
handling missing data. In the “Missing in Attributes” approach discussed by Tiwala et al.
(2008) and by Kapelner and Bleich (2015) for BART, the splitting rules are directly con-
structed to account for possible missingness. Such an approach could potentially be in-
corporated into the BART framework and allow one to handle missing covariates without
needing to specify a method for imputation.
In the AFT model discussed in Sections 2.1 and 2.3, the distribution of the residual
term is assumed to be the same for all values of the covariates. Greater flexibility may
be gained by relaxing this assumption by considering an additional “heteroskedastic” AFT
model which allows the residual distribution to change with the covariates. Although we
do not fully explore the use of a heteroskedastic model in this work, one approach for
modifying the nonparametric AFT model would be to allow the scale parameter of the
residual density to depend on the patient covariates while having the mixing distribution
remain independent of these covariates. One direct way of allowing the scale parameter to
vary with the covariates would be to use a parametric log-linear model as described in the
approach of Bleich and Kapelner (2014).
We note that our approach models the regression function m(A,x) for all values of A
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and x in order to compute treatment effect contrasts m(1,x)−m(0,x) and as such, requires
modeling of both the “main effects” and the treatment-covariate interactions. This general
approach to analyzing HTE - referred to as “global outcome modeling” by Lipkovich et al.
(2016) - may be contrasted with other approaches that only seek to directly model the
treatment effects without any consideration of the main effects. Modified outcome meth-
ods such as those described in Tian et al. (2014) and Weisberg and Pontes (2015) analyze
modified response variables whose expectations have the desired treatment effects, and this
approach allows one to directly estimate treatment-covariate interaction effects without
having to model the main effects. Adopting an approach similar to this would be straight-
forward with our accelerated failure time model. One would only need to create modified
responses by multiplying the observed log-failure times with an appropriate function of
treatment assignment. These new responses would now exhibit different form of censor-
ing, but this could easily be incorporated into our data augmentation procedure used in
posterior sampling.
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A Approximate Distribution of the Residual Variance
As discussed in Section 2.4 of the main paper, the variance of the residual term may be
expressed as
Var(W |G, σ) = σ2 + σ2τ
∞∑
h=1
pih
σ2τ
(τ ∗h − µG∗)
2 (19)
When assuming (as we do) that σ2τ = κ, this becomes
Var(W |G, σ) = σ2τ
[
σ2/κ+
∞∑
h=1
pih
σ2τ
(τ ∗h − µG∗)
2
]
(20)
Because we assume that G ∼ CDP (M,G0) with G0 as a Normal(0, σ
2
τ ) distribution, the
term [(τ ∗h − µG∗)
2]/σ2τ has a standard normal distribution.
In Section 2.4 of the main paper, it is stated that the prior distribution of Var(W |G, σ)
is approximated with the following distribution
σ2τ
[
ν/χ2ν +Normal(1, {2(M + 1)}
−1)
]
. (21)
The above approximation relies on the fact that
∑
∞
h=1
πh
σ2τ
(τ ∗h − µG∗)
2 has an approximate
Normal(0, {2(M + 1)}−1) distribution in the sense described by Yamato (1984). A his-
togram of simulated values of
∑
∞
h=1
πh
σ2τ
(τ ∗h − µG∗)
2 along with a plot of the approximating
Normal(0, {2(M+1)}−1) density is shown in Figure 8. In this figure, histograms are shown
for the cases of M = 25 and M = 50.
In Figure 9, we display a quantile-quantile plot of simulated values from the distribution
of Var(W |G, σ) vs. the approximate theoretical quantiles obtained from the approximate
prior distribution stated in (21).
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Figure 8: Histogram of simulated values of
∑
∞
h=1
πh
σ2τ
(τ ∗h −µG∗)
2 along with the approximat-
ing Normal{1, 2/(M + 1)} density. Simulations were performed with M = 25 and M = 50
for the mass parameter. In each case, 500 simulated values of a were drawn.
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Figure 9: Quantile-Quantile plot with simulated values of Var(W |G, σ) (using equation).
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